Jon A. Weidanz

Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24.

ATR blockade reduces IFN-gamma production in lymphocytes in vivo and in vitro.

Attenuation of acute rejection in a rat liver transplantation model by a liver-targeted dextran prodrug of methylprednisolone.

Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.

Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing.

Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes.

A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17.

Identification of breast cancer peptide epitopes presented by HLA-A*0201.

Assessing vaccine potency using TCRmimic antibodies.

Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer.

rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer.

Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells.

Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties.

TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models.

Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection.

A novel vascular targeting strategy for brain-derived endothelial cells using a TCR mimic antibody.

TCR mimic monoclonal antibodies induce apoptosis of tumor cells via immune effector-independent mechanisms.

Expanding the targets available to therapeutic antibodies via novel disease-specific markers.

TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells.

Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.

A novel T-cell receptor mimic defines dendritic cells that present an immunodominant West Nile virus epitope in mice.